Hsien-Yuan Lane

List of Publications by Year
in descending order

83 papers	3,910 citations	147801 31 h-index	128289 60 g-index
84 all docs	84 docs citations	84 times ranked	3466 citing authors

#	Article	IF	Citations
1	Predicting Anticancer Drug Resistance Mediated by Mutations. Pharmaceuticals, 2022, 15, 136.	3.8	4
2	Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2022, 25, 545-555.	2.1	20
3	Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms. Pharmacology Biochemistry and Behavior, 2022, 213, 173335.	2.9	7
4	De Novo Peptide and Protein Design Using Generative Adversarial Networks: An Update. Journal of Chemical Information and Modeling, 2022, 62, 761-774.	5.4	12
5	Suicide Ideation among Outpatients with Alcohol Use Disorder. Behavioural Neurology, 2022, 2022, 1-7.	2.1	2
6	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
7	Antihistamine promotes electroacupuncture analgesia in healthy human subjects: A pilot study. Journal of Traditional and Complementary Medicine, 2022, , .	2.7	1
8	Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People With Mild Cognitive Impairment: A Two-Year Prospective Study. International Journal of Neuropsychopharmacology, 2022, 25, 660-665.	2.1	7
9	Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment. Journal of Personalized Medicine, 2022, 12, 835.	2.5	0
10	Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial. International Journal of Neuropsychopharmacology, 2021, 24, 392-399.	2.1	23
11	Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease. Clinical Psychopharmacology and Neuroscience, 2021, 19, 135-144.	2.0	5
12	Effects of the Health-Awareness-Strengthening Lifestyle Program in a Randomized Trial of Young Adults with an At-Risk Mental State. International Journal of Environmental Research and Public Health, 2021, 18, 1959.	2.6	6
13	Plasma <scp>d</scp>-glutamate levels for detecting mild cognitive impairment and Alzheimerâ€™s disease: Machine learning approaches. Journal of Psychopharmacology, 2021, 35, 265-272.	4.0	24
14	Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2283.	4.1	39
15	Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. International Journal of Molecular Sciences, 2021, 22, 2146.	4.1	36
16	Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions. Scientific Reports, 2021, 11, 6922.	3.3	14
17	Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2761.	4.1	82
18	Risk Assessment for Heroin Use and Craving Score Using Polygenic Risk Score. Journal of Personalized Medicine, 2021, 11, 259.	2.5	5

#	Article	IF	Citations
19	Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia. JAMA Network Open, 2021, 4, e216156.	5.9	28
20	In Reply: Trough Melatonin Levels Have No Physiological or Clinical Relevance. Clinical Psychopharmacology and Neuroscience, 2021, 19, 393-393.	2.0	0
21	Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection. Scientific Reports, 2021, 11, 10179.	3.3	10
22	Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry. Molecules, 2021, 26, 4457.	3.8	3
23	Deep Learning with Neuroimaging and Genomics in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 7911.	4.1	26
24	An Investigation into Smartphone Addiction with Personality and Sleep Quality among University Students. International Journal of Environmental Research and Public Health, 2021, 18, 7588.	2.6	26
25	Molecular Basis of Late-Life Depression. International Journal of Molecular Sciences, 2021, 22, 7421.	4.1	24
26	Novel Therapeutic Approaches for Alzheimerâ€™s Disease: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 8208.	4.1	62
27	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	2.0	11
28	From Menopause to Neurodegenerationâ€”Molecular Basis and Potential Therapy. International Journal of Molecular Sciences, 2021, 22, 8654.	4.1	24
29	Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment. International Journal of Molecular Sciences, 2021, 22, 9718.	4.1	14
30	d-Amino Acids and pLG72 in Alzheimerâ€™s Disease and Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 10917.	4.1	14
31	Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments. Clinical Psychopharmacology and Neuroscience, 2021, 19, 577-588.	2.0	12
32	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study. Antioxidants, 2021, 10, 1839.	5.1	15
33	Efficiency of an Online Health-Promotion Program in Individuals with At-Risk Mental State during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 11875.	2.6	4
34	Benzoate treatment for adolescent anti-NMDAR encephalitis. Schizophrenia Research, 2020, 222, 472-473.	2.0	2
35	Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design. Molecules, 2020, 25, 3250.	3.8	51
36	An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways. Frontiers in Bioengineering and Biotechnology, 2020, 8, 569.	4.1	21

#	Article	IF	Citations
37	Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2020, 34, 495-505.	4.0	25
38	Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 509-518.	2.2	29
39	Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 771-780.	2.2	5
40	d-glutamate and Gut Microbiota in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 2676.	4.1	86
41	Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Current Drug Targets, 2020, 21, 610-615.	2.1	14
42	Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches. International Journal of Molecular Sciences, 2020, 21, 969.	4.1	65
43	D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. Pharmacology Biochemistry and Behavior, 2019, 185, 172760.	2.9	50
44	pLG72 levels increase in early phase of Alzheimerâ€™s disease but decrease in late phase. Scientific Reports, 2019, 9, 13221.	3.3	13
45	C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2621-2627.	2.2	5
46	The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. Frontiers in Pharmacology, 2019, 10, 540.	3.5	29
47	Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. Journal of Psychopharmacology, 2019, 33, 1030-1033.	4.0	19
48	Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning: A case series. Psychiatry and Clinical Neurosciences, 2019, 73, 348-348.	1.8	2
49	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. Frontiers in Psychiatry, 2019, 10, 93.	2.6	51
50	Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2019, 33, 436-448.	4.0	33
51	Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder. Journal of Affective Disorders, 2019, 245, 1119-1125.	4.1	17
52	Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry, 2018, 84, 422-432.	1.3	95
53	Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches. Frontiers in Psychiatry, 2018, 9, 566.	2.6	30
54	Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimerâ€™s Disease, and Parkinsonâ€™s Disease. Frontiers in Psychiatry, 2018, 9, 91.	2.6	40

#	Article	IF	Citations
55	Brain Stimulation in Alzheimer's Disease. Frontiers in Psychiatry, 2018, 9, 201.	2.6	98
56	Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World Journal of Biological Psychiatry, 2017, 18, 357-368.	2.6	72
57	Machine learning and systems genomics approaches for multi-omics data. Biomarker Research, 2017, 5, 2.	6.8	147
58	Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Scientific Reports, 2017, 7, 14849.	3.3	71
59	Acute Amino Acid <scp>d</scp>-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms. Journal of Agricultural and Food Chemistry, 2017, 65, 10792-10803.	5.2	27
60	Genetic Biomarkers on Age-Related Cognitive Decline. Frontiers in Psychiatry, 2017, 8, 247.	2.6	33
61	Decreased mRNA expression for the two subunits of system xcâ^', SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. Journal of Psychiatric Research, 2016, 72, 58-63.	3.1	61
62	Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics, 2015, 16, 555-566.	1.3	37
63	Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Molecular Psychiatry, 2014, 19, 636-637.	7.9	31
64	The C-Terminal Region of G72 Increases D-Amino Acid Oxidase Activity. International Journal of Molecular Sciences, 2014, 15, 29-43.	4.1	21
65	Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry, 2014, 75, 678-685.	1.3	106
66	NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2014, 20, 5169-5179.	1.9	60
67	NMDA Pathology and Treatment of Schizophrenia. Current Pharmaceutical Design, 2014, 20, 5118-5126.	1.9	18
68	Evaluation of psychometric properties of the Chinese Mandarin version Stateâ€Trait Anxiety Inventory Y form in Taiwanese outpatients with anxiety disorders. Journal of Psychiatric and Mental Health Nursing, 2013, 20, 499-507.	2.1	37
69	Add-on Treatment of Benzoate for Schizophrenia. JAMA Psychiatry, 2013, 70, 1267.	11.0	194
70	NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease. Current Neuropharmacology, 2012, 10, 272-285.	2.9	75
71	Assessing Gene-Gene Interactions in Pharmacogenomics. Molecular Diagnosis and Therapy, 2012, 16, 15-27.	3.8	58
72	Genderâ€Specific Differences in Susceptibility to Lowâ€Dose Methadoneâ€Associated QTc Prolongation in Patients with Heroin Dependence. Journal of Cardiovascular Electrophysiology, 2012, 23, 527-533.	1.7	26

#	Article	IF	Citations
73	Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior, 2012, 100, 665-677.	2.9	132
74	Sensitivity and specificity of the Chinese version of the Schizotypal Personality Questionnaire-Brief for identifying undergraduate students susceptible to psychosis. International Journal of Nursing Studies, 2010, 47, 1535-1544.	5.6	21
75	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 451.	2.1	159
76	Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biological Psychology, 2010, 83, 79-83.	2.2	28
77	A model testing factors that influence physical activity for Taiwanese adults with anxiety. Research in Nursing and Health, 2008, 31, 476-489.	1.6	19
78	Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study. Biological Psychiatry, 2008, 63, 9-12.	1.3	161
79	Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia. Biological Psychiatry, 2006, 60, 645-649.	1.3	182
80	Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia. Archives of General Psychiatry, 2005, 62, 1196.	12.3	263
81	Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 2004, 55, 452-456.	1.3	325
82	Shifting From Haloperidol to Risperidone for Behavioral Disturbances in Dementia: Safety, Response Predictors, and Mood Effects. Journal of Clinical Psychopharmacology, 2002, 22, 4-10.	1.4	18
83	Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 723-739.	4.8	80